依达拉奉治疗急性脑梗死的疗效观察

The Clinical effect observation of Edaravone for acute cerebral infarction

目的观察和验证依达拉奉治疗急性脑梗死的治疗效果。方法161例确诊急性脑梗死患者随机分为两组。治疗组给予依达拉奉30mg加生理盐水250ml静脉滴注,每天2次,共14天,余治疗同对照组。治疗前后定期(入院当日、第7天、第14天、第21天)对患者进行美国国立卫生院卒中患者神经机能缺损评分量表(NIHSS)及日常生活活动能力量表(ADL)评定,并判断临床疗效。结果2周后治疗组较对照组患者NIHSS评分明显降低,P<0.05;日常生活指数行为能力明显提高,P<0.05。治疗组无明显不良反应。结论依达拉奉治疗急性脑梗死安全有效。

Objective To observate and verify the clinical effect of Edaravone on the patients of acute cerebral infarction. Methods The case-control trail was carried out. 120 inpatients of acute cerebral infarction were randomly divided into two groups, including and control group. Edaravone was infused at a dose of 30mg, twice a day, for 14 days. The therapies of the control group were similar to those of Edaravone group except for Edaravone. The index included National Institutes of Health Stroke（NIHSS） and Barthel exponent of different time （day14, day21）. Results NIHSS was significantly decreased in the Edaravone group compared with the control group（P〈0.05） and Barthel exponent was increased（P〈0.05） after 14 day the patients inpatiented. Conclusions Edaravone is effective and safe for treating acute cerebral infarction.